ArticleVeterinary research communications2010
Protection of mice against Brucella abortus 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides.
Article in Veterinary research communications, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Meta-Analysis and Advancement of Brucellosis Vaccinology.PloS one · 2016Pooled it
- Identifying immunoreactive proteins in brucellin for enhanced brucellosis diagnosis: a proteomic approach.Frontiers in microbiology · 2025Article
- Immune response and protective efficacy of an experimentally developed inactivated oil adjuvantJournal of advanced veterinary and animal research · 2024Article
- A subunit vaccine based onActa biochimica et biophysica Sinica · 2024Article
- Immunoinformatics analysis of Brucella melitensis to approach a suitable vaccine against brucellosis.Journal, genetic engineering & biotechnology · 2023Article
- Immunization of mice with chimeric protein-loaded aluminum hydroxide and selenium nanoparticles induces reduction ofClinical and experimental vaccine research · 2023Article
- LDH as an adjuvant makesIranian journal of basic medical sciences · 2023Article
- Design of a new multi-epitope vaccine againstEpidemiology and infection · 2021Article
- Omp16, a conserved peptidoglycan-associated lipoprotein, is involved in Brucella virulence in vitro.Journal of microbiology (Seoul, Korea) · 2020Article
- Development and trial of vaccines againstJournal of veterinary science · 2017Review
- Evaluation of immunogenicity and protective efficacy of a liposome containing Brucella abortus S19 outer membrane protein in BALB/c mice.Iranian journal of veterinary research · 2016Article
- Progress inFrontiers in biology · 2013Article
- A history of the development of Brucella vaccines.BioMed research international · 2013Review
- Protective effects of recombinant Brucella abortus Omp28 against infection with a virulent strain of Brucella abortus 544 in mice.Journal of veterinary science · 2012Article
- What have we learned from brucellosis in the mouse model?Veterinary research · 2012Review
- Immunization of mice with recombinant protein CobB or AsnC confers protection against Brucella abortus infection.PloS one · 2012Article
- Article
- Immunogenic Consideration of a Designed Polypeptide Against Brucellosis Compared to RB51: AnAvicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brucella abortus, a gram negative, facultative intracellular pathogen causes brucellosis in many animal species and humans. Although live, attenuated vaccines are available against this infection, they suffer from certain limitations. Therefore, the development of an effective subunit vaccine against brucellosis is an area of intense research. The outer membrane proteins (OMPs) of Brucella species have been extensively studied for its immunogenicity and protective ability. We have investigated the potential of CpG ODN to enhance the immunogenicity and protective efficacy of recombinant 28 kDa outer membrane protein (rOMP28) of Brucella melitensis. The study demonstrated vigorous immunoglobulin G (IgG) response of OMP28. The administration of rOMP28 with CpG caused increased cell mediated immune response in terms of induced IgG2a, T-cell proliferation and up-regulation of type I cytokine expression. In contrast, the free antigen suppressed the interferon gamma (type I cytokine) production on in-vitro stimulation of spleenocytes. The result indicates the role of OMP28 in the down regulation of IFN-gamma production. Moreover, the B. abortus S-19 vaccinated mice showed highest production of IL-4 and IFN-gamma. The protective ability of the antigen was evaluated by systemic bacterial clearance after challenging the mouse with B. abortus 544 pathogen. The level of protection was significant in rOMP28+CpG treated mice but was lower than the required level. The results of the present study indicate that rOMP28 could be an immunogen capable of inducing both humoral and cellular immune response. The humoral response was biased towards Th1 type when it was co-administered with CpG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.